NES ZIONA, Israel, September 8, 2015
NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle delivery device, for use with Immune Design’s oncology immunotherapy products from its ZVex discovery platform.
The agreement will provide Immune Design non-exclusive access and supply for use of the device in all of its relevant cancer immunotherapy programs globally. Financial terms were not disclosed.
Yotam Levin, Chief Executive Officer of NanoPass, said, “We are thrilled about this collaboration with Immune Design, which expands our scope and marks our entry into the growing field of cancer immunotherapy. We believe reliable injection into the skin is critical for successful activation of specific, broad, and effective anti-tumor immune responses.”
About Immune Design
Immune Design is a clinical-state, public biotechnology company developing in vivo immunotherapies engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.
About Cancer Immunotherapy
Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent clinical trials1 , and cancer immunotherapy was announced “Breakthrough of The Year 2013” by Science magazine2.
About NanoPass Technologies Ltd
NanoPass Technologies is a pioneer in the development and commercialization of intradermal delivery of vaccines and immunotherapy. NanoPass has concluded multiple clinical studies in various fields including vaccines (influenza, polio and others3), cancer and allergy immunotherapy.
MicronJet is a microneedle-based device for intradermal delivery of vaccines and drugs. MicronJet600 is registered for marketing in various territories including the USA, Europe, Canada, China and Korea, for use by health care professionals for intradermal delivery (see label).
1. Ira Mellman et al. Cancer immunotherapy comes of age. Nature. 2011 Dec 21;480(7378):480-9.
2. Jennifer Couzin-Frankel. Cancer Immunotherapy. Science 2013 20 Dec. Vol 342. 1432-3.
3. Levin Y. et al. Clinical evaluation of a novel microneedle device.. Are all intradermal delivery methods the same? Vaccine. 2014;(32):4249-52.